Question 1

What is the catalog number for (3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488?

Accepted Answer

The catalog number for (3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488 is 160929.

Question 2

What sizes are available for (3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488?

Accepted Answer

(3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488 is available in the following size(s): 50 mg.

Question 3

Is (3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488 in stock?

Accepted Answer

(3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 4

Is this product classed as hazardous or restricted for shipping?

Accepted Answer

Some products are subject to special import/export regulations, dangerous goods handling, or licensing requirements. Where this applies, it’s noted on the product page, and any required extra documents or fees will be confirmed with you before dispatch, never added without your consent.

Question 5

Can you help me confirm if this product is right for my specific experiment?

Accepted Answer

Yes, contact us with details of your sample type, species, and intended application, and our specialists will confirm suitability or suggest an alternative from our supplier network if this isn’t the best fit.

Question 6

What is the purity of this recombinant protein?

Accepted Answer

Purity, typically assessed by SDS-PAGE, is listed on the datasheet under quality control data.

(3S) -1-Azabicyclo[2.2.2]octan-3-ol discontinued. See 288488

Product Specifications

Frequently Asked Questions

Explore Other Products

CD8 (RIV11), CF647 conjugate, 0.1mg/mL

MUC1 / CA15-3 / EMA / CD227 (Epithelial Marker) (VU-11D1), CF405S conjugate, 0.1mg/mL

HLA-Aw32 & HLA-A25 (MHC I) (CATA-1), CF640R conjugate, 0.1mg/mL

CD54 / ICAM-1 (15.2), CF647 conjugate, 0.1mg/mL

Human IgG Immunoglobulin (IG266), CF740 conjugate, 0.1mg/mL

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF488A conjugate, 0.1mg/mL